A clonal competition assay showing populations of cells with different mutations. Depending on the mutation, each population of cells is stained a different color. Credit: Larissa Haertle / CNIO Not all cells within the same cancer are the same. They all have genetic errors that turn them into tumor cells, but these errors are not...
Tag: <span>multiple myeloma (MM)</span>
Post
Epigenetic test could help predict efficacy of immunotherapy in multiple myeloma
Epigenetic characterization of PVR shows the correlation between promoter DNA methylation and expression. Credit: Leukemia (2024). DOI: 10.1038/s41375-024-02419-z Multiple myeloma is a type of blood cancer that appears mainly after the age of 60. Its incidence, therefore, increases with the aging of the population. In this pathology, the bone marrow, the porous structure within the bones that...
Post
Cilta-cel found highly effective in first real-world study of patients with relapsed or refractory multiple myeloma
Credit: Pixabay/CC0 Public Domain In the first study to report real-world outcomes from ciltacabtagene autoleucel (cilta-cel), a chimeric antigen receptor (CAR)-T therapy for multiple myeloma, patients experienced efficacy and safety results similar to those seen in clinical trials, according to results published in Blood. Of 236 patients who received cilta-cel infusions at 16 U.S. medical centers in 2022,...
Post
Anti-myeloma agent opens for new treatment strategy
The tumour form multiple myeloma is very challenging to treat and is still considered incurable. In a recently published study in the scientific journal Oncotarget, researchers at Uppsala University show how inhibition of the protein BMI-1 could be used as a new strategy to treat the disease. Multiple myeloma is a type of blood cancer where immune cells grow in...
Post
New antibody uses 1-2 punch to potentially treat blood cancers
Antibody PF-06747143 both attacks AML tumor cells and moves them from the nurturing bone marrow environment into the peripheral blood streams, where they are more vulnerable. Researchers have developed a two-pronged approach to blood cancer treatment: 1) attacking cancer cells directly and/or 2) driving them from the nurturing bone marrow environment into the peripheral blood...